July 14th 2022
An overview of the frontline treatment armamentarium for patients with transplant-ineligible multiple myeloma and review of the MAIA and SWOG-S0777 trials.
Before closing out their discussion on transplant-eligible NDMM, expert panelists consider the role of maintenance therapy following transplant.
July 6th 2022
Expert perspectives on the optimal duration of treatment in patients with transplant-eligible newly diagnosed multiple myeloma.
Comprehensive discussion on the assessment of response to frontline therapy for transplant-eligible multiple myeloma and the role of MRD negativity in assessing response.
June 29th 2022
Shared insight on clinical trial results from both the GRIFFIN and MASTER trials, and the key role of frontline quadruplet regimens in transplant-eligible NDMM.
Expert hematologist-oncologists open their discussion on NDMM management by reviewing frontline data from the recent DETERMINATION trial.
September 16th 2021
Krina K. Patel, MD, MSc, discusses mitigating CAR T-cell therapy–related cytokine release syndrome in multiple myeloma.
September 8th 2021
Krina K. Patel, MD, MSc, discusses the integration of CAR T-cell therapy into the treatment paradigm of relapsed/refractory multiple myeloma.
August 24th 2021
Krina K. Patel, MD, MSc, discusses future research directions with CAR T-cell therapy in patients with multiple myeloma.
August 18th 2021
Krina K. Patel, MD, MSc, discusses the potential utility of elranatamab in multiple myeloma.